US appeal denied in Czech blood plasma saga

A Liechtenstein company has failed in its latest bid to enforce a US$400 million award against the Czech Republic in the US courts, as its founder pursues a related investment treaty claim worth US$2.5 billion.


Get unlimited access to all Global Arbitration Review content